Theravance Bio Ord (TBPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 10,417 | 14,649 | 12,451 | 11,050 | 13,196 |
| Gross Profit | 10,417 | 14,649 | 12,451 | 11,050 | 13,196 |
| Operating Expenses | 35,329 | 32,080 | 26,653 | 34,151 | 50,419 |
| Operating Income | -24,912 | -17,431 | -14,202 | -23,101 | -37,223 |
| Interest Expense | 550 | 550 | 1,545 | 2,137 | 2,137 |
| Other Income | 2,979 | 3,722 | -276 | 2,440 | -375 |
| Pre-tax Income | -22,483 | -14,259 | -16,023 | -22,798 | -39,735 |
| Income Tax | -395 | -510 | 0 | -5 | 524 |
| Net Income Continuous | -22,088 | -13,749 | -16,023 | -22,793 | -40,259 |
| Net Income Discontinuous | N/A | 3,387 | 932,654 | 14,602 | 14,313 |
| Net Income | $-22,088 | $-10,362 | $916,631 | $-8,191 | $-25,946 |
| EPS Basic Total Ops | -0.35 | 0.16 | 12.14 | -0.11 | -0.34 |
| EPS Basic Continuous Ops | -0.35 | -0.22 | -0.21 | -0.30 | -0.53 |
| EPS Basic Discontinuous Ops | N/A | 0.38 | 12.35 | 0.19 | 0.19 |
| EPS Diluted Total Ops | -0.35 | 0.16 | 12.14 | -0.11 | -0.34 |
| EPS Diluted Continuous Ops | -0.35 | -0.22 | -0.21 | -0.30 | -0.53 |
| EPS Diluted Discontinuous Ops | N/A | 0.38 | 12.35 | 0.19 | 0.19 |
| EBITDA(a) | $-24,965 | $-17,111 | $-13,405 | $-22,165 | $-36,241 |